Sunscreen
Phase 3Small molecule
Sunscreen is one of 52 small molecule programs targeting Skin rash. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
73 competitors in Skin Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Afinitor
NovartisPhase 3
Aldara
BBausch Health Americas, Inc.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Peridex
MMedline Industries
Phase 3
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 3
Libtayo
RegeneronPhase 2
Iressa
AstraZenecaPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Actos
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Cancer1 trial
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Completed·—·Phase 2·NCT01867294·19 enrolled
Skin rash1 trial
Melasma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sunscreen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYale University